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RESEARCH AND THEORY
Performing Economic Evaluation of Integrated Care: 
Highway to Hell or Stairway to Heaven?
Apostolos Tsiachristas*, K. Viktoria Stein†, Silvia Evers‡ and  
Maureen Rutten-van Mölken§
Health economists are increasingly interested in integrated care in order to support decision-makers to 
find cost-effective solutions able to tackle the threat that chronic diseases pose on population health and 
health and social care budgets. However, economic evaluation in integrated care is still in its early years, 
facing several difficulties. The aim of this paper is to describe the unique nature of integrated care as a 
topic for economic evaluation, explore the obstacles to perform economic evaluation, discuss methods and 
techniques that can be used to address them, and set the basis to develop a research agenda for health 
economics in integrated care. The paper joins the voices that call health economists to pay more attention 
to integrated care and argues that there should be no more time wasted for doing it.
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Introduction 
Health economists are increasingly interested in  integrated 
care for chronic conditions. This is because the rapidly 
increasing prevalence of chronic conditions reduces popu-
lation’s health, increases the demand for health and social 
care [1]. It also has negative macroeconomic consequences 
for consumption (i.e. reduced demand), capital accumula-
tion (i.e. less investments), labour productivity (i.e. less out-
put per working hour) and labour supply (i.e. availability of 
human resources). [2]. Health economists support health-
care decision makers with evidence in finding an adequate 
response to these challenges by studying the changes in 
demand for healthcare, investigating the efficiency of 
health technologies, studying their financing mechanisms, 
and advocating the efficient allocation of scarce resources. 
The findings of health economics support decision-makers 
to define the right mixture of healthcare interventions to 
maximise the health and well-being of society as well as to 
meet the preferences and needs of patients. 
One of these responses is the provision of integrated 
care. This refers to “initiatives that seek to improve 
outcomes for those with (complex) chronic health prob-
lems and needs by overcoming fragmentation through 
linkage or coordination of services of different provid-
ers along the continuum of care” [3]. It puts the patients 
and their individual needs and preferences in the centre 
and organizes care around them. Integrated care is seen 
as a promising means to increase productive efficiency in 
care for people with chronic conditions [4]. According to 
the triple aim framework, as advocated by the Institute 
for Healthcare Improvement, integrated care aims to 1) 
improve population health, 2) improve patient experience 
with care, and 3) reduce costs [5]. 
Economic evaluation in integrated care is still in its 
early years. It faces several difficulties mainly due to the 
fact that integrated care is a complex package of inter-
ventions with unclear definition, composition, and 
application, which deviates substantially from simple 
interventions that are traditionally subject to health eco-
nomic analysis. However, the urge for a wider implemen-
tation of integrated care to address the needs of people 
with chronic conditions and improve efficiency calls for 
more evidence-based decision-making based on thorough 
economic evaluations. The existing evidence about the 
economic impact of integrated care available in the thin 
scientific literature is inconclusive [3]. The main reasons 
are the great variation in interventions, and the relatively 
weak methodological approaches to evaluate integrated 
care [6]. Many studies have called for more reliable and 
replicable economic evaluation of integrated care [7] and 
recognised that current evaluative frameworks may not be 
sufficient to address complex interventions [8], because 
these interventions require different costing methods and 
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their outcomes extend beyond Quality Adjusted Life Years 
(QALYs). Therefore, a modified framework with extended 
costing methods and outcome metrics that include the 
non-health benefits (e.g. satisfaction) of integrated care 
may be needed. 
The aim of this paper is to describe the unique nature of 
integrated care as a topic for economic evaluation, explore 
the obstacles to perform economic evaluation, discuss 
methods and techniques that can be used to address 
them, and set the basis to develop a research agenda for 
health economics in integrated care. The following sec-
tions are structured along the components of economic 
evaluations as suggested in guidelines issued by health 
technology assessment agencies in Europe [9]. 
Integrated care defined as complex intervention
Health technologies such as medicines, diagnostic tests, 
medical devices, and surgical procedures are considered to 
be “simple” interventions because they are usually deliv-
ered by one care provider or provider organisation and the 
outcome is a result of the intervention and the interaction 
between the patient and the caregiver. Complex interven-
tions are different. Their common characteristics include 
one or more of the following: a) various interacting com-
ponents, b) targeting groups or organizations rather than 
or in addition to individuals, c) a variety of intended (and 
unintended) outcomes, d) they are amendable to tailor-
ing through adaptation to the context in which they are 
introduced and learning by feedback loops of patient- and 
provider-experiences and outcomes, and e) effectiveness 
is impacted by behaviour of those delivering and receiving 
the intervention [10]. Figure 1 illustrates how a complex 
intervention is diffused to different groups of recipients, 
interacts, and impacts different outcomes. Integrated 
care is a good example of a complex intervention. The 
World Health Organization (WHO) defines it as “a con-
cept bringing together inputs, delivery, management and 
organization of services related to diagnosis, treatment, 
care, rehabilitation and health promotion. Integration is 
a means to improve services in relation to access, quality, 
user satisfaction and efficiency” [11]. Similar definitions 
of integrated care can be found elsewhere [12, 13]. Based 
on the WHO definition, integrated care may be considered 
an ultra-complex intervention or according to Shiell et al., 
2008 a complex system [14]. This is because integrated 
care is composed of multiple complex interventions (e.g. 
computerised decision support and self-management 
support), it behaves in a non-linear fashion (i.e. change 
in output is not proportional to change in input), and 
the interventions interact with the context in which they 
are implemented. For example, the Chronic Care Model 
(CCM), on which many integrated care programmes have 
been based, provides a framework of elements that must 
be considered when developing improvement strategies 
Figure 1: Illustration of complex intervention.
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for providing care for people with chronic conditions, 
originally including: (a) self-management support, (b) 
decision support, (c) delivery system design, (d) clinical 
information systems, (e) health care organization, and (f) 
community resources and policies [15]. 
Comparator
Economic evaluation is a comparative analysis. Even if it 
is not possible to identify control groups, the relative effi-
ciency of integrated care still needs to be assessed. In gen-
eral, comparators used in economic evaluations frequently 
include active comparators such as current practice, best 
available alternative, or alternative levels of treatment 
intensity, different variations of similar programs etc. 
Identifying an appropriate comparator for integrated care 
is challenging. Standard practice, frequently called “usual 
care”, is often an appropriate control but it can be at least 
as complex as the intervention being evaluated and may 
change over time by national or regional policy reforms 
that stimulate the evolution of usual care for an individual 
with one or more chronic conditions towards integrated 
care. As a result, usual care may have become a low inten-
sity integrated care. Comparing integrated care models 
that differ in terms of their intensity or comprehensive-
ness maybe a good alternative when appropriate control 
groups without integrated care are difficult to identify [16, 
17]. However, the room for improvement by implement-
ing a more intense or comprehensive programme may 
be reduced. Hence, the competing alternatives to be con-
sidered in an economic evaluation include: a) integrated 
care (complex intervention) to simple interventions 
delivered in current clinical practice, b) integrated care 
to usual care (considered also as complex intervention), 
c) various components of integrated care to each other 
or the sequence in which they were introduced, or d) all 
the above. Although, it is not straightforward which pair 
of competing alternatives to choose and each option has 
pros and cons, evaluation guidelines suggest the evalua-
tion of a complex health intervention accompanied by a 
detailed description of the components rather than disen-
tangling the effects of the individual components [10, 18]. 
Arguably, the interdependence of the interventions cre-
ates synergy effects. As a result the total cost-effectiveness 
of integrated care is not a linear summation of the par-
tial cost-effectiveness of the interventions provided. For 
example, a thorough diagnostic assessment, which is not 
followed by a mutually agreed treatment package based 
on a patient’s personal goals is unlikely to be of benefit 
to the patient [19]. However, the benefits of the latter are 
likely to be greater when based on a broad assessment of 
impairments, symptoms, functional limitations, disease 
perceptions, health behaviour and quality of life.
Study design and data
Most evaluation studies of integrated care are obser-
vational studies and very often lack a control group [6]. 
Besides the difficulty of creating an appropriate control 
group, other reasons for adopting an observational design 
include financial considerations, difficulties in identifying 
suitable participants, concerns about the generalizability 
of the results, and ethical considerations [20]. However, 
observational studies raise major concerns about the 
potential sources of bias and confounding factors that 
may jeopardize attribution of effect (or causality). Experi-
mental designs such as randomised clinical trials (RCTs) are 
considered as the most robust designs to infer causality. 
Since integrated care includes interventions on organiza-
tional level and the risk of contamination (i.e. the control 
group is affected by the intervention) is high, cluster-RCTs 
could be considered as an adequate study design. Even in 
that case, experimental designs may face similar problems 
as observational studies in inferring causality when evalu-
ating complex interventions such as integrated care. This 
is due to hidden differences in the context with which the 
treatment and control groups interact that may critically 
affect the results [21]. Standardization of interventions 
would be a solution to replicate the results in other set-
tings but in the case of integrated care, it would preclude 
its adaptability to the local context and would treat it as 
a simple intervention [22]. Moreover, it is recognised that 
health interventions that are observed to be efficacious 
and cost-effective in the context of highly structured ran-
domized trials may not be effective or cost-effective once 
they are made available in practice, under less controlled 
conditions [23].
Quasi-experimental designs or natural experiments 
may be the best alternative when evaluating integrated 
care because they involve the application of experimen-
tal thinking to non-experimental situations. They widen 
the range of interventions beyond those that are amend-
able to planned experimentation and they encourage a 
rigorous approach to use observational data [24]. Natural 
experiments are applicable when control groups are iden-
tifiable and when groups are exposed to different levels 
of intervention. Natural experiments using regression 
adjustment and propensity-score matching could reduce 
observed confounding between the comparators while, 
difference-in-differences, instrumental variables, and 
regression discontinuity could reduce the unobserved 
confounding between the comparators. A combination of 
these techniques is also possible in the evaluation [25]. 
Figure 2 provides an overview of study designs to be con-
sidered in the evaluation depending on the availability of 
a control group and degree of experimenting. 
Data availability and quality is another important factor 
to be considered when choosing a study design. Routine 
data might be of good quality and comprehensiveness 
but it can be costly or time consuming to access it and 
lengthy procedures can be applicable to merge data from 
different sources as confidentiality should be secured. In 
addition researchers have lack of control of the type of 
outcome measures included in the routinely collected 
data. In the absence or inadequacy of routine data, survey 
data could be used in the economic evaluation. However, 
the quality of survey data depends on the validity of the 
questionnaire, the response rate, the missing observa-
tions, and data comprehensiveness (consider that lengthy 
surveys with many measures lead to low response rates). 
Ideally, routine data would be combined with survey 
data in the evaluation of integrated care and would be 
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interpreted with the support of data collected from quali-
tative research. However, a complete economic evaluation 
based on different data sources requires substantial finan-
cial and human resources. Even when resources are not an 
issue, lack of evaluation culture, related shortage of capac-
ity and reluctance of payers or providers to engage in 
evaluation might challenge the evaluation of integrated 
care [28].
Evaluation period
Most guidelines issued by health technology assessment 
agencies worldwide suggest to adopt a lifetime horizon 
in economic evaluation of medical innovations [29]. How-
ever, most evaluation studies of integrated care had an 
evaluation period of a year and some were extended up to 
3 years [6]. This short to medium-term evaluation period 
may fail to capture the full effect of integrated care. This is 
because it takes at least 3–5 years for health management 
initiatives to identify “true” programme effectiveness due 
to lags in full implementation [30]. This may not even be 
long enough to study the effects of the preventive inter-
ventions in the integrated care package. However, adopt-
ing a follow-up period longer than 5 years may increase 
the risk of failing to attribute effects to integrated care 
because in the long-term, the intervention and eventu-
ally control groups are contaminated with other inter-
ventions and health policy reforms [31]. Common sense 
would suggest to consider the start and end points of inte-
grated care to determine an adequate evaluation period 
but none of these points is clear-cut in integrated care. An 
exact baseline measurement for evaluation is often hard 
to determine because the preparation and development 
of some integrated care interventions may have occurred 
way before that point. Failing to capture these efforts 
would underestimate the development costs of integrated 
care [32]. Determining the end point of integrated care is 
challenging as well. Integrated care interventions may be 
delivered one-off (e.g. 8 sessions of self-management sup-
port) or repeatedly (e.g. monitoring of high risk patients, 
establishment of multi-disciplinary teams, and develop-
ment of integrated ICT system). Thus, the (partial) effects 
of integrated care are expected to be recurrent in time.
A way of extending the evaluation period without 
extending the official research period, is to set up a con-
tinuous routine monitoring system that tracks a core 
set of outcomes over time, not as part of the research 
but as part of routine practice. This can guide managers, 
healthcare providers, and payers, and may even be used 
to motivate patients when they have access to their own 
outcome data. The challenge is to choose this core set, 
which eventually will have to change over time to reflect 
continuous improvement and changing objectives that 
are to stakeholders. 
Outcome measures
Integrated care, as being a complex intervention, impacts 
many outcomes on different levels. These outcomes 
could be categorised in process indicators of the organi-
zation and delivery of care, patient’s satisfaction with 
care, access to care, informal caregivers’ satisfaction and 
quality of life, patients’ lifestyle and risk factors, patients’ 
ability to self-manage and cope with disease, clinical out-
comes, functional status, quality of life, wellbeing, and 
mortality [3, 33, 34]. Besides objective outcome measures 
(e.g. blood tests, smoking status, date of death) the out-
comes can be measured with patient-reported outcomes 
Figure 2: Study designs by type and level of allocation.
Source: adapted from a series of RAND reports [20, 26, 27].
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measures (PROMS), patient-reported experience  measures 
(PREMS), and patient activation measures (PAMs). These 
outcomes encompass the argument of Huber et al., 
that health should be defined more dynamically, based 
on the resilience or capacity to cope and maintain and 
restore one’s integrity, equilibrium, and sense of wellbe-
ing [35] as well as the capabilities approach of Amartya 
Sen including ‘empowerment’ which can be viewed as a 
type of capability that measures the ‘ability of a person 
to function’ [36, 37]. Even advocates of QALYs as meas-
urement to support decision-making would argue that 
all of these outcomes cannot be captured in a single unit 
of measurement. Moreover, literature suggests that the 
QALY may not be relevant for decision-making at the level 
of provider organisations and insurers, when reimburse-
ment decisions have already been made at national or 
regional level [38]. In that case, the decision that needs 
to be taken is not whether to fund integrated care but 
which type of programme should be provided, to whom 
and how in day-to-day practice. Thus, QALY is not a rel-
evant measurement to be used in clinical decision sup-
port systems, which are primarily informed by changes 
in clinical outcomes, health risk factors, care processes, 
and behaviour. Multiple outcome measures, measured at 
multiple levels (e.g. patient, GP practice, and community) 
and eventually from different perspectives (e.g. providers 
and patient) should be employed to assess whether the 
triple aim of integrated care has been reached. However, 
the measurement burden, especially for frontline clini-
cians, should not be underestimated.
Some of these outcome measures could be used to 
inform performance indicators to facilitate the provi-
sion of financial incentives for integrating care. This 
would go beyond the performance indicators currently 
used in pay-for-performance schemes (e.g. in England 
[39]) by informing integrated care specific indicators 
and group specific indicators (e.g. disadvantaged peo-
ple or people with multi-morbidity). Examples of such 
measures have been issued by WHO and include for 
example care planning and coordination, shared deci-
sion making, and medication review in older adults 
[40]. Looking at the care continuum, performance indi-
cators could be assigned with different importance in 
time. For example indicators of physical improvements 
may be more important in the short term and indica-
tors of psychological and social improvements in the 
long term for a patient who had a stroke. Furthermore, 
absolute and relative performance indicators could be 
combined to stimulate high-performing providers to 
maintain their performance levels and motivate low-
performing providers to achieve relatively high perfor-
mance [41, 42]. However, financial incentives linked 
to individual process or outcome indicators have been 
found to have unwanted effects like a reduction in 
focus on unmeasured outcomes and gaming strategies. 
Perhaps financial incentives linked to population-level 
outcomes can overcome these effects, although this 
involves the challenge of creating a mutual sense of 
shared responsibility among providers to achieve these 
outcomes.
Measurement and valuation of costs
Similar to outcomes, integrated care also impacts a broad 
range of costs, inside and outside the health care system. 
As a result, the societal perspective (i.e. considering all 
costs at societal level) is preferred to the narrower health 
care perspective when estimating the costs of integrated 
care. A full societal perspective would include the impact 
of integrated care on all sectors of the society (e.g. social 
care, workforce, education, security and justice). However, 
such a perspective would demand complex, time-con-
suming, and costly data collection and cost calculation. 
Thus, health economists may want to restrict the soci-
etal perspective to include only those societal costs that 
are expected to be impacted by the integrated care pro-
gramme under evaluation. For example, costs in the edu-
cation and justice sectors might be relevant for inclusion 
in an economic evaluation of integrated care programmes 
for adolescents with mental conditions but not for a pro-
gramme targeting adults with diabetes. Furthermore, 
integrate care programmes require substantial develop-
ment costs (including but not limited to training costs, ICT 
costs, and costs of redesigning the care delivery process) 
and implementation costs (such as multidisciplinary team 
meetings, the costs of coordination between care-givers, 
the costs of monitoring and feedback). These costs are 
commonly carried by the organization that implements 
the programme and should be included in the economic 
evaluation. 
A “minimum” set of cost categories relevant in the evalu-
ation of integrated care may include [33, 43]: 1) the devel-
opment costs of integrated care, 2) the implementation 
costs of integrated care, including process oriented costs, 
3) the costs of health and social care utilization (includ-
ing long-term care), 4) the costs of informal care and 5) 
the costs of productivity loss due to absence from paid 
work or reduced productivity while at work. But again, the 
selection or relevant cost categories depends on the con-
text. For example, if an already developed integrated care 
programme was implemented in another setting, then the 
development costs would not be relevant for inclusion in 
the analysis. 
Development and implementation costs of integrated 
care could be collected via surveys or interviews with 
managers or financial controllers of integrated care pro-
grammes. A study systematically collected these costs by 
using a template based on the CostIt instrument of the 
World Health Organisation (WHO) [32, 44]. This study 
could provide inspiration on how to treat overhead and 
capital costs as well as how to amortize development costs 
of integrated care. 
Measuring and valuing all other cost categories could 
follow current practices and guidelines in health eco-
nomic literature. The costs of health and social care utili-
zation could be measured retrospectively by standardised 
questionnaires like the Client Service Receipt Inventory 
(CSRI) [45] or based on routine or claims data. The CSRI 
also includes questions for residential care, criminal jus-
tice service and state benefits. Patient travelling costs and 
productivity costs could also be collected via standardized 
surveys [46]. Developing and applying questionnaires to 
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measure resource use customized to a study would be 
an alternative of using existing questionnaires but this 
would require additional research time to validate them 
[47]. Unit costs could be gathered similar to traditional 
economic evaluations [48]. When national average unit 
cost prices are not available or not precise enough, activ-
ity-based costing may be a useful alternative in estimat-
ing service costs of integrated care [49, 50]. However, this 
approach is very costly and in many cases impractical to 
be performed in large scale economic evaluations [51].
Broader economic evaluation 
Considering the broad range of health and non-health 
outcomes for inclusion in the evaluation of integrated 
care, the adoption of cost-benefit analysis (CBA) -in which 
all benefits are expressed in monetary terms- and cost-
effectiveness analysis (CEA) -in which the effects are meas-
ured in natural units (e.g. life years gained)- is precluded 
because these methods have a single measure of outcome 
[48, 52]. Even if all outcomes of integrated care could be 
expressed in monetary terms and included in CBA [53], it 
would be very time-consuming and costly to do so and the 
objections against assigning monetary values on health 
would still remain [37]. Performing a cost-utility analysis 
(CUA), which is the most widely used evaluation method 
and believed to have a comprehensive outcome meas-
ure, might be problematic in the case of integrated care 
because as mentioned earlier, a QALY does not capture 
the non-health benefits of integrated care (e.g. patient 
satisfaction with the process of care delivery). Therefore, a 
cost-consequence analysis (CCA) seems an adequate alter-
native because it presents a range of outcomes alongside 
costs. CCA probably fits better with real-world decision-
making, in which decisions are made based on other cri-
teria besides cost-effectiveness but it does not support 
a systematic ranking of alternative interventions based 
on their cost-effectiveness [54]. Multi-Criteria Decision 
Analysis (MCDA) could overcome this limitation of CCA by 
supporting a systematic comparison of different alterna-
tives based on their performance on various pre-specified 
criteria (i.e. a range of outcomes and costs) [54]. In this 
process, different criteria are weighted according to their 
relative importance to the decision by different stakehold-
ers, including patients. Hence, MCDA is a sophisticated 
method for comparing complex interventions, such as 
integrated care, incorporating all relevant categories of 
outcomes and costs [55, 56].
A framework to evaluate integrated care based on 
MCDA is reported in the literature [33]. The challenge for 
performing MCDA in this context is to determine a set of 
criteria relevant for decision-making and assign weights 
based on the preferences of stakeholders in integrated 
care. Whether the new composite measure that results 
from a MCDA can include other criteria than health and 
non-health benefits (e.g. costs) is debated [57, 58]. If the 
new composite measure only includes benefits, then a 
new incremental cost-effectiveness ratio (ICER) threshold 
value for one unit of additional benefit on this compos-
ite measure may need to be determined to support reim-
bursement decisions. However, MCDA may also be used 
alongside and as a supplement to the existing deliberate 
process, serving to structure the discussions and feed back 
to decision makers the weights implicit in their decisions 
[59]. This may particularly apply when other criteria than 
benefits are included in the composite measure. Inter-
sectoral costs and consequences may also be addressed by 
combining CCA and MCDA [60].
Determinants of cost-effectiveness
Similar to many complex interventions, the cost-effective-
ness of integrated care depends on the provided inter-
ventions and their combination. There is evidence about 
the (cost-) effectiveness of most interventions included in 
integrated care [40, 61–64]. However, theoretical and con-
ceptual studies on integrated care strongly suggest that 
the value of integrated care is in the combination of inter-
ventions. This is because integrated care “is not a discrete 
and immediately replicable intervention and its elements 
should be treated as a totality” [65]. Ham (2010) argues 
that the tenth characteristic of a high performing chronic 
care system is the link between individual interventions 
that transforms them into a coherent whole and has an 
additional effect [66]. It is unclear whether this effect of 
combining different interventions is additive or multipli-
cative but it surely is the synergy and interaction between 
interventions that contributes to the overall effect. There-
fore, the evaluation of integrated care should be under-
taken at an aggregated level [22]. Moreover, the complex-
ity of integrated care in terms of intervention intensity 
[27] and comprehensiveness [16] as well as its uptake and 
successful implementation [67] may impact outcomes 
and costs. Especially the development and implementa-
tion costs would increase with complexity [32]. The tar-
get population is another determinant of integrated care 
cost-effectiveness [17]. This may largely be explained by 
the fact that integrated care involves behavioural aspects. 
Literature shows that behaviour interventions are highly 
cost-effective but not for everyone [68]. This notion is also 
shared by the National Institute for Health and Care Excel-
lence (NICE) in England where thorough subgroup analy-
sis is recommended when evaluating behavioural change 
interventions [18]. Finally, the existence of economies of 
scale and economies of scope may influence development 
and implementation costs of integrated care and there-
fore its cost-effectiveness.
Policy evaluation and implementation analysis
The implementation of integrated care in many coun-
tries was supported by new forms of financing and pay-
ments [7, 69, 70]. This is because adequate funding and 
payment systems with financial incentives that steer 
behaviour towards collaboration between professionals 
are prerequisites for the successful implementation of 
integrated care [2, 71]. Examples include the reduction 
in co-payments for patients participating in disease man-
agement programmes in France, the performance based 
payment system in England that stimulates GP adher-
ence to clinical guidelines, the bundled payment in The 
Netherlands where care groups receive a single annual 
payment for a patient to cover the (mostly primary) care 
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for a particular chronic disease. Positive evidence from the 
 implementation of such financial incentives and payment 
schemes is reported in the literature [72–76]. 
These incentives may either be considered as behav-
ioural interventions that are part of an integrated care pro-
gramme or they may be seen as part of the local context 
with which the integrated care programme interacts. In 
the former case, a broad policy evaluation may accommo-
date the implementation of integrated care and accom-
panying payment reforms simultaneously. In the latter 
case, payment reforms could be seen as strategies to suc-
cessfully implement integrated care. As a result, the appli-
cation of Value of Implementation analysis [77, 78] may 
be employed to provide the overall cost-effectiveness of 
implementing integrated care with the support of finan-
cial incentives. However, it would be hard to disentangle 
the impact of the payment reform from the effect of the 
care reform on health care expenditure and care quality.
Standardised reporting 
Reporting of methods and results should be systematised 
to allow traceability and transferability of the health eco-
nomic evidence in integrated care. A thorough description 
of the interventions provided as part of integrated care, 
and eventually in the control group, including their tim-
ing and intensity and the involved providers should provide 
a clear understanding of “what” was evaluated. The meth-
ods employed and the assumptions made in the economic 
evaluation should also be clearly stated regarding the 
“how” was it evaluated and the results of subgroup analysis 
should highlight “for whom” it was cost-effective. Existing 
statements such as the CHEERS statement [79], the STROBE 
statement for observational studies [80], and the disease 
management quality assessment instrument developed by 
Steuten et al., [81] could be used to standardize reporting. 
Including a periodic evaluation and detailed documenta-
tion of the provided interventions (including the control 
group, if available) in the stream of integrated care inter-
ventions, could provide meaningful information about the 
full and sustainable cost-effectiveness of integrated care.
Discussion and research agenda
The complexity of integrated care and the substantial 
resources needed to collect reliable data appears to have 
challenged health economists to evaluate the cost-effec-
tiveness of integrated care to date. Economic evaluations 
published in health economic journals mostly focus on 
single elements of integrated care [82–86]. There is need 
for that to change and health economists to understand 
the peculiarities of integrated care as intervention under 
evaluation. Recently, the Journal of Health Economics 
issued a call for a special issue on integrated care. This is 
certainly a step forward. On the health services research 
side, health economists were not involved in many eval-
uation studies so far, which presumably resulted in low 
quality evidence on cost-effectiveness. Economic evalu-
ations are frequently piggy back tailed in the effective-
ness evaluation of integrated care but this needs to be 
changed because there is a clear need for better under-
standing and communication between health economists, 
researchers from other disciplines, clinicians, payers and 
 decision-makers during the set-up of an evaluation study.
Since economic evaluation could facilitate the (re-)
designing of integrated care, funding for methodologi-
cal research in this field should be available to health 
economists [87]. International collaboration of health 
economists should work on the methodological chal-
lenges, exchange experience in economic evaluations, 
and issue guidelines for best evaluation practice. The 
Health Economics Special Interest Group (HE-SIG) of the 
International Foundation for Integrated Care (IFIC) is an 
example of such an initiative [88]. This paper is an initial 
attempt to address the challenges for a thorough eco-
nomic evaluation of integrated care and provide possible 
solutions to overcome them (Box 1). It could become a 
stepping stone for future discussion of health economists 
in the HE-SIG and other related groups. 
Similar to previous studies [8], this paper suggests to 
extend or use the current health economic methods cor-
rectly in integrated care, rather than to invent new ones. 
It joins voices that call for a broader economic evaluation 
of integrated care. A consensus should be reached about 
whether this could be achieved with the proposed method 
of employing a cost-consequence analysis operationalized 
by an application of MCDA or by adopting a more wel-
farist approach such as a cost-benefits analysis, which is 
popular among health economists for evaluating public 
health interventions [89]. In this discussion, policy mak-
ers should also be involved after having been presented 
with the pros and cons of each evaluation method. In the 
case where MCDA is employed in the economic evalua-
tion, researchers should determine a core set of criteria 
relevant for decision making in integrated care and assign 
their weights from an international perspective to allow 
cross-national comparisons of integrated care models. 
Moreover, it would be interesting if future studies 
would investigate differences in access to integrated care 
programmes by socio-economic status and region. The 
economic evaluations should address equity issues such 
as whether integrated care should be provided to every-
one in need or only to those who are expected to increase 
its cost-effectiveness. Consensus about costing methods 
(e.g. when to use activity based-costing instead of existing 
unit costs in integrated care) has to be reached and instru-
ments to assess the study quality in economic evaluation 
of integrated care similar to existing ones [81, 90] have to 
be developed.
Special attention should be paid to multi-morbidity 
because it requires more complex care than the care 
needed to treat single chronic conditions. More com-
plexity means more challenges for health economists to 
evaluate integrated care for people with multi-morbidity 
and more resources needed for the evaluation. Modelling 
the effects and costs of patients with multi-morbidity is 
an obstacle in performing economic evaluation because 
most disease progression models are disease specific and 
include only some concordant co-morbidities (e.g. myo-
cardial infarct in a diabetes type two model). Development 
of more comprehensive disease progression models is 
 necessary in this matter.
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Several models have been developed to evaluate com-
plex interventions [91–94]. Their common elements are 
the importance of using behavioural theory and mixed-
methods to understand the mechanisms that drive the 
effectiveness of a complex intervention. From an economic 
evaluation perspective, this is important in determining 
the mechanisms that influence costs and outcomes and 
designing a study capable of answering the questions: 
which interventions, for which patients, in which settings, 
using which resources? As a result, these theories and 
methods should be further explored in the future in order 
to systematize their inclusion in the economic evaluation 
of integrated care. In addition, health economics should 
support policy makers in Eastern and South European 
countries, where action plans to integrate care have been 
recently published to support policy makers in taking the 
first serious steps towards that direction [95, 96]. A thor-
ough economic evaluation should be integral part of their 
implementation to inform decision making. 
Beyond the scope of economic evaluation, health 
economists may further investigate the economic conse-
quences of ageing, the impact of integrated care on the 
demand and supply of health and social care and health 
insurance, the efficiency of integrated care systems, meth-
ods to incorporate the results of economic evaluation in 
financial agreements, and the suitability and impact of 
current and innovative financing and payment schemes 
for delivering integrated care. A comprehensive contribu-
tion of health economics in paving the way towards inte-
grated care may be the stairway to policy makers’ heaven.
Conclusion
This paper joins the voices that call health economists to 
pay more attention to integrated care. The complexity of 
this intervention should be seen as a challenge for health 
economists to explore new dynamics in this research 
field. The solutions to the challenges described in this 
paper may be the basis for future research. This is the 
best time to expand health economics towards integrated 
care because the urgency to increase efficiency in care for 
chronic conditions is increasing rapidly. Health care deci-
sion makers need evidence on integrated care now.
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